Despite evidence supporting GLP‐1 RAs as effective weight loss drugs, there is limited data on their long‐term effects in breast cancer patients, creating a significant knowledge gap insufficiently addressed in existing literature. This evidence concerns the gene GLP1R and breast carcinoma.